- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-1-1-mer
- Ligands
- 3 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA.3: 10 residues within 4Å:- Chain A: E.216, L.266, N.267, F.380, G.383, R.447, C.448, V.449, S.450
- Ligands: NAG.19
2 PLIP interactions:2 interactions with chain A- Hydrophobic interactions: A:V.449
- Hydrogen bonds: A:V.449
NAG-NAG-BMA.5: 8 residues within 4Å:- Chain D: E.216, L.266, N.267, N.381, G.383, V.449, S.450
- Ligands: NAG.39
1 PLIP interactions:1 interactions with chain D- Hydrogen bonds: D:G.383
NAG-NAG-BMA.6: 11 residues within 4Å:- Chain F: E.216, V.259, L.266, N.267, F.380, G.383, R.447, C.448, V.449, S.450
- Ligands: NAG.61
2 PLIP interactions:2 interactions with chain F- Hydrophobic interactions: F:V.449
- Hydrogen bonds: F:V.449
- 55 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.7: 4 residues within 4Å:- Chain A: C.136, T.137, N.138, R.148
Ligand excluded by PLIPNAG.8: 2 residues within 4Å:- Chain A: N.141, N.142
Ligand excluded by PLIPNAG.9: 4 residues within 4Å:- Chain A: S.155, F.156, N.157, K.168
Ligand excluded by PLIPNAG.10: 2 residues within 4Å:- Chain A: N.202
- Chain D: R.313
Ligand excluded by PLIPNAG.11: 3 residues within 4Å:- Chain A: N.239, T.241, S.279
Ligand excluded by PLIPNAG.12: 3 residues within 4Å:- Chain A: D.235, K.236, N.246
Ligand excluded by PLIPNAG.13: 3 residues within 4Å:- Chain A: N.281, T.283, N.284
Ligand excluded by PLIPNAG.14: 2 residues within 4Å:- Chain A: N.306, I.327
Ligand excluded by PLIPNAG.15: 4 residues within 4Å:- Chain A: N.300, T.302, H.334, N.336
Ligand excluded by PLIPNAG.16: 1 residues within 4Å:- Chain A: N.359
Ligand excluded by PLIPNAG.17: 5 residues within 4Å:- Chain A: N.367, S.368, S.369, T.376
- Ligands: NAG.18
Ligand excluded by PLIPNAG.18: 4 residues within 4Å:- Chain A: T.376, N.390, S.392
- Ligands: NAG.17
Ligand excluded by PLIPNAG.19: 4 residues within 4Å:- Chain A: N.267, S.296, N.451
- Ligands: NAG-NAG-BMA.3
Ligand excluded by PLIPNAG.20: 4 residues within 4Å:- Chain A: Q.298, N.300, R.447, V.449
Ligand excluded by PLIPNAG.21: 5 residues within 4Å:- Chain A: E.272, E.273, E.274, N.294, K.348
Ligand excluded by PLIPNAG.22: 3 residues within 4Å:- Chain A: N.343, S.397, W.399
Ligand excluded by PLIPNAG.23: 1 residues within 4Å:- Chain A: N.396
Ligand excluded by PLIPNAG.24: 2 residues within 4Å:- Chain B: N.100, T.102
Ligand excluded by PLIPNAG.25: 3 residues within 4Å:- Chain B: N.107, S.109, E.110
Ligand excluded by PLIPNAG.26: 4 residues within 4Å:- Chain B: K.122, E.123, S.125, N.126
Ligand excluded by PLIPNAG.27: 3 residues within 4Å:- Chain C: N.100, T.102, I.130
Ligand excluded by PLIPNAG.28: 1 residues within 4Å:- Chain C: N.126
Ligand excluded by PLIPNAG.29: 3 residues within 4Å:- Chain C: S.17
- Chain D: E.92, N.93
Ligand excluded by PLIPNAG.30: 3 residues within 4Å:- Chain D: F.156, N.157, K.168
Ligand excluded by PLIPNAG.31: 3 residues within 4Å:- Chain D: N.182, N.202, T.203
Ligand excluded by PLIPNAG.32: 5 residues within 4Å:- Chain D: N.239, T.241, I.277, S.279, H.356
Ligand excluded by PLIPNAG.33: 3 residues within 4Å:- Chain D: D.235, T.245, N.246
Ligand excluded by PLIPNAG.34: 2 residues within 4Å:- Chain D: N.281, T.283
Ligand excluded by PLIPNAG.35: 3 residues within 4Å:- Chain D: N.306, I.327, V.445
Ligand excluded by PLIPNAG.36: 5 residues within 4Å:- Chain D: N.300, T.302, H.334, N.336, T.418
Ligand excluded by PLIPNAG.37: 2 residues within 4Å:- Chain D: N.343, W.399
Ligand excluded by PLIPNAG.38: 5 residues within 4Å:- Chain D: N.367, S.392, N.396
- Ligands: NAG.43, NAG.44
Ligand excluded by PLIPNAG.39: 4 residues within 4Å:- Chain D: N.267, S.296, N.451
- Ligands: NAG-NAG-BMA.5
Ligand excluded by PLIPNAG.40: 3 residues within 4Å:- Chain D: N.138, T.140, G.149
Ligand excluded by PLIPNAG.41: 4 residues within 4Å:- Chain D: Q.298, N.300, S.416, R.447
Ligand excluded by PLIPNAG.42: 1 residues within 4Å:- Chain D: N.359
Ligand excluded by PLIPNAG.43: 3 residues within 4Å:- Chain D: N.390, S.392
- Ligands: NAG.38
Ligand excluded by PLIPNAG.44: 4 residues within 4Å:- Chain D: S.392, G.393, N.396
- Ligands: NAG.38
Ligand excluded by PLIPNAG.45: 2 residues within 4Å:- Chain E: N.100, T.102
Ligand excluded by PLIPNAG.46: 3 residues within 4Å:- Chain E: N.107, S.109, E.110
Ligand excluded by PLIPNAG.47: 4 residues within 4Å:- Chain E: K.122, E.123, S.125, N.126
Ligand excluded by PLIPNAG.48: 3 residues within 4Å:- Chain E: S.17
- Chain F: E.92, N.93
Ligand excluded by PLIPNAG.49: 1 residues within 4Å:- Chain F: N.157
Ligand excluded by PLIPNAG.50: 4 residues within 4Å:- Chain F: V.139, N.153, Y.170, L.172
Ligand excluded by PLIPNAG.51: 3 residues within 4Å:- Chain A: R.313
- Chain F: N.202, T.203
Ligand excluded by PLIPNAG.52: 4 residues within 4Å:- Chain F: W.101, N.239, T.241, S.279
Ligand excluded by PLIPNAG.53: 3 residues within 4Å:- Chain F: D.235, T.245, N.246
Ligand excluded by PLIPNAG.54: 2 residues within 4Å:- Chain F: N.281, T.283
Ligand excluded by PLIPNAG.55: 3 residues within 4Å:- Chain F: E.274, N.294, E.295
Ligand excluded by PLIPNAG.56: 4 residues within 4Å:- Chain F: Q.298, N.300, N.336, S.338
Ligand excluded by PLIPNAG.57: 2 residues within 4Å:- Chain F: N.306, I.327
Ligand excluded by PLIPNAG.58: 4 residues within 4Å:- Chain F: N.300, T.302, H.334, N.336
Ligand excluded by PLIPNAG.59: 2 residues within 4Å:- Chain F: N.343, W.399
Ligand excluded by PLIPNAG.60: 3 residues within 4Å:- Chain F: T.376, N.390, S.392
Ligand excluded by PLIPNAG.61: 4 residues within 4Å:- Chain F: N.267, S.296, N.451
- Ligands: NAG-NAG-BMA.6
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Cottrell, C.A. et al., Priming antibody responses to the fusion peptide in rhesus macaques. Npj Vaccines (2024)
- Release Date
- 2024-05-22
- Peptides
- Surface protein gp120: ADF
Transmembrane protein gp41: BCE
Base4 Heavy Chain: G
Base4 Light Chain: H - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AD
EF
FB
BC
CE
DG
HH
L
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-1-1-mer
- Ligands
- 3 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 55 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Cottrell, C.A. et al., Priming antibody responses to the fusion peptide in rhesus macaques. Npj Vaccines (2024)
- Release Date
- 2024-05-22
- Peptides
- Surface protein gp120: ADF
Transmembrane protein gp41: BCE
Base4 Heavy Chain: G
Base4 Light Chain: H - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AD
EF
FB
BC
CE
DG
HH
L